The committee set up set up by the National Drug Safety Agency (ANSM) published the report, in which experts plead for the development of the law to allow the use of this plant, in particular to relieve pain. However, they are only recommending it for specific cases and by other means than smoking the plant, taking into account the associated health risks.
"The committee considers it appropriate to authorize the use of the therapeutic cannabis for patients in particular clinical situations”, says the report.
First set of conclusions from the ANSM in France; Therapeutics Cannabis should be accessible to French patients. More work to come on the prescription and dispensing mechanics. But the medical community is taking a historic stance. https://t.co/4eUsx7O4jG #FRANCE #CannabisHélène Moore (@HLN_Moore) 13 December 2018
Cannabis is said to be successful in pain reduction associated with the treatment of certain severe forms of epilepsy, and for patients being treated for a cancer or in palliative care.
If France adopts the recommendation it would mark the first step towards legalising therapeutic cannabis and would be followed by market regulation and tracking patients to evaluate the risks and benefits.
Medical cannabis may not be available to French patients before 2020, said Nicolas Authier, head of the ANSM study.
France's medicines agency @ansm has recommended that medical cannabis be authorised for: 🔲 Chronic pain🔲 Some forms of severe and drug-resistant epilepsy🔲 Supportive care in oncology🔲 Palliative care🔲 Multiple sclerosis spasticity https://t.co/gx76WikDXICannabis Europa (@cannabiseuropa) 13 December 2018
More than thirty countries internationally, including many American states and Canada, authorise therapeutic cannabis. This includes 21 in the European Union, as well as Switzerland, Norway, Israel and Turkey.
The ANSM states in a press release that it will decide within the next few days what are the steps to take following the results of this report.